µÏÍþ¹ú¼Ê

    µÏÍþÖƵÏÍþ¹ú¼Ê µÏÍþÖƵÏÍþ¹ú¼Ê

    ¼ò ¤™
    • ¼ò
    • ·±
    • EN
    ¤œ
    Ïà¹ØÁ´½Ó
    • ½­ËÕºÀÉ­µÏÍþ¹ú¼ÊÒµ¼¯ÍÅÓÐÏÞ¹«Ë¾¥Y
    ÐÂÎÅ·¢²¼
    Press Release
    Ê×Ò³  >  ÐÂÎÅÖÐÐÄ  >  ÐÂÎÅ·¢²¼
    µÏÍþÖƵÏÍþ¹ú¼Ê | Ê¥ÂÞÀ³?»ñ¡¶ÑÓ»ºÂýÐÔÉöÔಡ½øÕ¹ÁÙ´²¹ÜÀíÖ¸ÄÏ£¨2025 Äê°æ£©¡·ÍƼö
    ·¢²¼ÈÕÆÚ£º2025/07/14
    ×ÖºÅ

    - Ê¥ÂÞÀ³?»ñµÃÖ¸ÄÏÍƼöÖ÷Òª»ùÓÚÒ»ÏîÕë¶Ô·Ç͸ÎöCKDƶѪ»¼ÕßµÄIIIÆÚÁÙ´²Ñо¿[1]¡£

    - ¸ÃÑо¿½á¹ûÏÔʾ£ºÔÚÖйú·Ç͸ÎöÉöÐÔƶѪ»¼ÕßÖУ¬Ê¥ÂÞÀ³?½öÐè4ÖÜ1´ÎƤÏÂ×¢É䣬¾ÍÄÜ´ïµ½Óë³£¹æ°¢·¨ÒÀ²´Í¡Í¬ÑùµÄÉýºì×÷Óã¬ÇÒÐÄѪ¹Ü²»Á¼Ê¼þ·¢ÉúÂʸüµÍ[2]¡£

    - Ä¿Ç°Ê¥ÂÞÀ³?Òѱ»ÄÉÈë¶à¸öÉöÔಡѧָÄÏ/¹²Ê¶ÀàÎļþÍƼö£¬³ä·Ö֤ʵÁËÆ䳤Ч»úÖƶÔÓÚÉöÐÔƶѪ»¼ÕßµÄÁÙ´²»ñÒ棬ÓÐÖú¸ÄÉÆÉöÐÔƶѪµÄ¹ÜÀí¡£


    ½üÈÕ£¬¡¶ÖлªÉöÔಡÔÓÖ¾¡··¢±íÁËÓɹúÄÚÉöÔಡѧ¼°Ïà¹ØÁìÓòµÄȨÍþר¼Ò¹²Í¬×éÖ¯±àдµÄÖйúÊײ¿¡¶ÑÓ»ºÂýÐÔÉöÔಡ½øÕ¹ÁÙ´²¹ÜÀíÖ¸ÄÏ£¨2025 Äê°æ£©¡·£¨ÒÔϼò³Æ£ºÖ¸ÄÏ£©£¬ÓɵÏÍþÖƵÏÍþ¹ú¼Ê×ÔÖ÷Ñз¢µÄ´´ÐµÏÍþ¹ú¼ÊÊ¥ÂÞÀ³?£¨ÅàĪɳëÄ×¢ÉäÒº£©±»ÄÉÈëÖ¸ÄÏÍƼö£¬ÓÃÓÚÂýÐÔÉöÔಡ£¨CKD£©ºÏ²¢Æ¶ÑªµÄÖÎÁƹÜÀí[1]¡£

    ¸ÃÖ¸ÄϽáºÏ×îеÄѭ֤ҽѧ֤¾ÝºÍר¼ÒÁÙ´²Êµ¼ù¾­Ñ飬ΪÁÙ´²Ò½Ê¦ÌṩÁË»ùÓÚ×îÐÂÖ¤¾ÝºÍÊʺϹúÇéµÄCKD¹ÜÀíʵ¼ùÖ¸µ¼¡£Ê¥ÂÞÀ³?ÊÇÄ¿Ç°ÉöÐÔƶѪÖÎÁÆÁìÓò¡¢È«ÇòΨһ»ñÅúÉÏÊеÄ1ÀàС·Ö×ÓëÄÀ໯ѧµÏÍþ¹ú¼ÊÎÆäÿÔÂÒ»´Î¸øµÏÍþ¹ú¼Ê·½Ê½£¬Ìî²¹Á˹úÄÚÉöÐÔƶѪÖÎÁÆÁìÓòÔÂÖƼÁ¿Õ°×¡£

    Ê¥ÂÞÀ³?¼ÈÍùÒѱ»ÄÉÈëÉöÔಡѧÁìÓòר¼Ò¹²Ê¶£¬°üÀ¨¡¶³¤Ð§ºìϸ°ûÉú³É´Ì¼¤¼ÁÖÎÁÆÉöÐÔƶѪÖйúר¼Ò¹²Ê¶£¨2024 Äê°æ£©¡·[3]ºÍ¡¶Ö¸µ¼ÉöÐÔƶѪ»¼Õß×ÔÎÒ¹ÜÀíµÄÖйúר¼Ò¹²Ê¶£¨2024°æ£©¡·[4]£¬Ö§³ÖÆ䳤Ч¸øµÏÍþ¹ú¼ÊÓÐÖúÌá¸ß»¼ÕßµÄÒÀ´ÓÐÔ£¬ÆäÏÔÖøµÄÉý¸ßѪºìµ°°××÷ÓúÍÁ¼ºÃµÄÐÄѪ¹Ü°²È«ÐÔÓÐÖú¸ÄÉÆÉöÐÔƶѪµÄÖÎÁƹÜÀíˮƽ¡£

    ±¾´ÎÊ¥ÂÞÀ³?»ñµÃÖ¸ÄÏÈÏ¿ÉÍƼöÖ÷Òª»ùÓÚÒ»ÏîÕë¶Ô·Ç͸ÎöCKDƶѪ»¼ÕߵĢóÆÚÁÙ´²Ñо¿¡£¸ÃÑо¿½á¹ûÏÔʾÅàĪɳëÄÔÚÖ÷ÒªÁÆЧÖÕµã[ÁÆЧÆÀ¹ÀÆÚѪºìµ°°×£¨HGB£©Ë®Æ½×Ô»ùÏßµÄƽ¾ù±ä»¯]ÉÏ·ÇÁÓÓÚ°¢·¨ÒÀ²´Í¡£¬°²È«ÐÔÉÏ×ÜÌåÏ൱£¬µ«ÅàĪɳëÄ×éÐÄѪ¹Ü²»Á¼Ê¼þ·¢ÉúÂʸüµÍ[¸´ºÏ°²È«ÐÔʼþ£º0.9% vs 3.4%£»ÆäËûÐÄѪ¹Üʼþ·¢ÉúÂÊ£º0% vs 5.2%][5]¡£

    ÊÀ½çÉöÔಡ´ó»á£¨WCN£©2025·¢²¼µÄÒ»Ïîʺó·ÖÎö½øÒ»²½Ö¤ÊµÁ˸âóÆÚÑо¿µÄ½áÂÛ¡£·ÖÎö±íÃ÷£¬Ïà±È°¢·¨ÒÀ²´Í¡£¬ÅàĪɳëÄÔÚÁÆЧÆÀ¹ÀÆÚÄÚµÄHGBÉý¸ß¸üΪÃ÷ÏÔ£¨P=0.0163£©£¬ÇÒÔÚÀÏÄ꣨¡Ý65Ë꣩ºÍ»ùÏßÉö¹¦ÄܽϲÕßÖÐÁÆЧ¸ü¼Ñ£¨P¾ù£¼0.05£©¡£·ÖÎö»¹·¢ÏÖ£¬ÅàĪɳëÄ×éÐèÒª²¹³äÌú¼Á¡¢Ò¶ËáºÍάÉúËØB12µÄ»¼Õß±ÈÀý¸üµÍ£¬ÌáʾÆä¿ÉÄÜÓÐÖúÌá¸ßÌåÄÚÌúÀûÓÃ[6]¡£

    ×÷ΪÉöÐÔƶѪÁìÓòÈ«ÇòΨһ»ñÅúÉÏÊеÄС·Ö×ÓëÄÀ໯µÏÍþ¹ú¼Ê£¬Ê¥ÂÞÀ³?ÒÔ´´ÐµķÖ×ӽṹ¡¢³¤Ð§Îȶ¨µÄ´Ùºì»úÖÆ£¬ÔÚÁÙ´²Êµ¼ùÖÐÕ¹ÏÖ³öµÄÁ¼ºÃµÄÁÆЧ¼°ÐÄѪ¹Ü°²È«ÐÔ£¬ÆäÓÐÍûÔÚ¸ÄÉÆÎÒ¹ú»¼ÕßÉöÐÔƶѪ¹ÜÀíµÄͬʱ£¬½øÒ»²½°ïÖúÔÚ¸ü¹ã·ºµÄÈËȺʵÏÖÑÓ»ºCKD½øÕ¹¡¢¸ÄÉÆCKD»¼ÕßÉú´æµÄÖØҪĿ±ê¡£

    Ö¸Äϱ³¾°¼°½¨Òé

    Ö¸Äϱ³¾°¼°½¨Òé

    CKDÊÇÑÏÖØΣº¦ÎÒ¹úÈËÃñ½¡¿µµÄÖØ´ó¼²²¡¡£Ëæ×Ų¡³Ì½øÕ¹£¬»¼Õ߿ɳöÏÖÈ«Éí¶àϵͳ²¢·¢Ö¢£¬²¢¿ÉÄÜ·¢Õ¹ÎªÖÕÄ©ÆÚÉö²¡£¨ESKD£©¡£ÑÓ»ºCKD½øÕ¹£¬ÒÔ½µµÍESKD·¢ÉúÂʺ͸÷ÖÖÑÏÖز¢·¢Ö¢·¢Éú·çÏÕÊÇCKDÖÎÁƵÄÖ÷ҪĿ±ê¡£Ö¸ÄÏÇ¿µ÷£¬CKDµÄÁÙ´²¹ÜÀíÄ¿±êÊÇ¿ØÖÆÔ­·¢²¡½øÕ¹£¬²¢¸ÄÉÆÓëCKDÏà¹ØµÄÁÙ´²±íÏֺͽá¾Ö£¬°üÀ¨Æ¶ÑªµÈµÈ[1]¡£

    ƶѪÊÇCKD»¼Õß×î³£¼ûµÄºÏ²¢Ö¢Ö®Ò»¡£CKD»¼Õß¼´Ê¹ºÏ²¢Çá¶ÈƶѪҲ»áÔö¼ÓCKD½øÕ¹ºÍESKD·¢Éú·çÏÕ£¬Í¬Ê±»¹Ôö¼ÓÐÄѪ¹ÜʼþºÍÈ«ÒòËÀÍö·çÏÕ£¬µ¼Ö»¼ÕßÕûÌåÉú»îÖÊÁ¿Ï½µ¡£Ö¸ÄϽ¨ÒéHGB¡Ü100 g/L µÄCKD »¼ÕßÆôÓðüÀ¨ÅàĪɳëÄÔÚÄڵĺìϸ°ûÉú³É´Ì¼¤¼Á£¨ESA£©ÀàµÏÍþ¹ú¼ÊÎïÖÎÁÆÉöÐÔƶѪ£»HGB?100 g/LµÄƶѪ»¼ÕßÈôÓÐÉý¸ßHGBˮƽÒÔ¸ÄÉÆÉú»îÖÊÁ¿ÐèÇóʱ£¬Ò²¿É¿¼ÂÇÅàĪɳëĵÈESAÀàµÏÍþ¹ú¼ÊÎï½øÐиöÌ廯ÖÎÁÆ[1]¡£

    ²Î¿¼ÎÄÏ×£º

    [1] ÑÓ»ºÂýÐÔÉöÔಡ½øÕ¹ÁÙ´²¹ÜÀíÖ¸ÄÏ£¨2025Äê°æ£©[J]. ÖлªÉöÔಡÔÓÖ¾, 2025, 41(6): 455-488.

    [2] Xie,Jianteng et al. Randomized Trial of Pegmolesatide for the Treatment of Anaemia in Patients with Non-Dialysis Chronic Kidney Disease. Kidney International Reports.2024.https://doi.org/10.1016/j.ekir.2024.12.002. In Press.

    [3]³¤Ð§ºìϸ°ûÉú³É´Ì¼¤¼ÁÖÎÁÆÉöÐÔƶѪÖйúר¼Ò¹²Ê¶£¨2024Äê°æ£©[J]. ÖлªÉöÔಡÔÓÖ¾,2024,40(2):146-157.

    [4]Ö¸µ¼ÉöÐÔƶѪ»¼Õß×ÔÎÒ¹ÜÀíµÄÖйúר¼Ò¹²Ê¶(2024 °æ). ÖйúѪҺ¾»»¯.2025,24(1):1-12

    [5]Xie,Jianteng et al. Randomized Trial of Pegmolesatide for the Treatment of Anaemia in Patients with Non-Dialysis Chronic Kidney Disease. Kidney International Reports.2024.https://doi.org/10.1016/j.ekir.2024.12.002. In Press.

    [6]Xueqing Yu,et al. Pegmolesatide for the Treatment of Anemia in Non-dialysis-dependent Chronic Kidney Disease Patients: Post-hoc Analysis of a Phase 3 Trial. WCN 2025. Abstract No: WCN25-679.

    ¹ØÓÚµÏÍþÖƵÏÍþ¹ú¼Ê

    µÏÍþÖƵÏÍþ¹ú¼ÊÊÇÖйúÁìÏȵĴ´ÐÂÇý¶¯ÐÍÖƵÏÍþ¹ú¼ÊÆóÒµ£¬ÒÔ¡¸³ÖÐø´´Ð£¬Ìá¸ßÈËÀàÉúÃüÖÊÁ¿¡¹ÎªÊ¹Ãü£¬Öصã¹Ø×¢¿¹Ö×Áö¡¢¿¹¸ÐȾ¡¢ÖÐÊàÉñ¾­ÏµÍ³¡¢´úл¼°×ÔÉíÃâÒßµÈÖØ´ó¼²²¡ÖÎÁÆÁìÓò¡£½ØÖÁÄ¿Ç°£¬¹«Ë¾ÒÑÉÏÊÐ7¿î´´ÐµÏÍþ¹ú¼Ê£¬ÐγÉÁ˷ḻµÄ²úÆ·¹ÜÏß¡£µÏÍþÖƵÏÍþ¹ú¼ÊÁ¬Ðø¶àÄêλ¾ÓÈ«ÇòÖƵÏÍþ¹ú¼ÊÆóÒµ°ÙÇ¿¡¢ÖйúÒ½µÏÍþ¹ú¼ÊÑз¢²úÆ·Ïß×î¼Ñ¹¤ÒµÆóҵǰ3Ç¿£¬Êǹú¼ÒÖصã¸ßм¼ÊõÆóÒµ¡¢¹ú¼Ò¼¼Êõ´´ÐÂʾ·¶ÆóÒµ¡£µÏÍþÖƵÏÍþ¹ú¼ÊÓÚ2019Äê6ÔÂÔÚÏã¸ÛÁª½»Ëù¹ÒÅÆÉÏÊУ¨¹ÉƱ´úÂ룺03692.HK£©¡£¸ü¶àÐÅÏ¢Çë·ÃÎÊ£º/¡£

    ÃâÔðÉùÃ÷

    ±¾ÎĽö¹©Ò½ÁÆÎÀÉúרҵÈËÊ¿²ÎÔÄ£¬·Ç¹ã¸æÓÃ;¡£µÏÍþÖƵÏÍþ¹ú¼Ê²»ÍƼöÈκÎδ»ñÅúµÏÍþ¹ú¼ÊƷʹÓúÍ/»òδ»ñÅúÊÊÓ¦Ö¢ÓõÏÍþ¹ú¼Ê£¬Ò಻¶ÔÈκεÏÍþ¹ú¼ÊÆ·ºÍ/»òÊÊÓ¦Ö¢×÷ÍƼö¡£±¾¹«¸æÖÐÉæ¼°µÄÐÅÏ¢½ö¹©²Î¿¼£¬Çë×ñ´ÓÒ½Éú»òÆäËûÒ½ÁÆÎÀÉúרҵÈËÊ¿µÄÒâ¼û»òÖ¸µ¼¡£Ò½ÁÆÎÀÉúרҵÈËÊ¿×÷³öµÄÈκÎÓëÖÎÁÆÓйصľö¶¨Ó¦¸ù¾Ý»¼ÕߵľßÌåÇé¿ö²¢×ñÕÕµÏÍþ¹ú¼ÊƷ˵Ã÷Êé¡£ÈçÐèÁ˽⹫˾ÈκβúÆ·¡¢Ò½ÁÆ»ò¼²²¡µÄÏà¹ØÐÅÏ¢£¬ÇëÎñ±Ø×ÉѯҽÁÆÎÀÉúרҵÈËÊ¿¡£

    Ç°Õ°ÐÔ˵Ã÷

    ±¾ÐÂΟåÖ¼ÔÚÌṩ¹ØÓÚµÏÍþÖƵÏÍþ¹ú¼Ê¼¯ÍÅÓÐÏÞ¹«Ë¾¼°Æ丽Êô¹«Ë¾£¨°üÀ¨Æä×Ó¹«Ë¾£¬Í³³ÆΪ¡°µÏÍþÖƵÏÍþ¹ú¼Ê¡±£©µÄÐÅÏ¢¡£Ëü²»¹¹³É¶ÔµÏÍþÖƵÏÍþ¹ú¼Ê»òÈκÎͶ×ʽ¨ÒéµÄÐÅÏ¢Åû¶¡£

    ±¾ÐÂΟå°üº¬µÄÐÅÏ¢¿ÉÄÜ°üÀ¨ÓëµÏÍþÖƵÏÍþ¹ú¼ÊÒµÎñºÍ²úÆ·Ç°¾°¡¢¼Æ»®¡¢ÐÅÄî¡¢Ô¤ÆںͲßÂÔÏà¹ØµÄÇ°Õ°ÐÔÉùÃ÷¡£ÕâЩÉùÃ÷ÊÇ»ùÓÚÍƲâÐÔ¼ÙÉèµÄÔ¤²â£¬²¢²»±£Ö¤Î´À´µÄ±íÏÖ¡£ËüÃÇÊܵ½ÖîÈç¿Æѧ¡¢ÉÌÒµ¡¢ÕþÖΡ¢¾­¼Ã¡¢²ÆÎñ¡¢·¨ÂÉÒòËØÒÔ¼°¾ºÕù»·¾³ºÍÉç»áÌõ¼þµÈ·çÏպͲ»È·¶¨ÐÔµÄÓ°Ï죬ÕâЩÒòËغܶ඼ÊǵÏÍþÖƵÏÍþ¹ú¼ÊÎÞ·¨¿ØÖÆÇÒÄÑÒÔÔ¤²âµÄ£¬Òò´Ëʵ¼Ê½á¹û¿ÉÄÜÓë´Ë´¦ËùÊöÓÐÏÔÖø²îÒ죬ÇÒ¹ýÈ¥µÄ֤ȯ¼Û¸ñÇ÷ÊƲ»Ó¦×÷ΪδÀ´ÐÐÇéµÄÖ¸µ¼¡£Òò´Ë£¬Í¶×ÊÕßÔÚʹÓÃÕâЩÐÅÏ¢½øÐÐͶ×ʾö²ßʱӦ½÷É÷ÐÐÊ¡£¡°ÖÂÁ¦ÓÚ¡±¡°Ô¤ÆÚ¡±¡°ÏàÐÅ¡±¡°Ô¤²â¡±¡°Òâͼ¡±¡°Ô¤¼Æ¡±¡°¿ÉÄÜ¡±¡°½«¡±¡°Ó¦¸Ã¡±¡°¼Æ»®¡±¡°¼ÌÐø¡±¡°Ä¿±ê¡±¡°¿¼ÂÇ¡±¡°¹À¼Æ¡±¡°Ö¸µ¼¡±¡°Ç±ÔÚ¡±¡°×·Çó¡±ÒÔ¼°ÓÚÈκÎδÀ´¼Æ»®¡¢Ðж¯»òʼþµÄÌÖÂÛÖÐʹÓõÄÀàËÆ´ÊÓïºÍÊõÓ¾ù±íʾǰհÐÔÉùÃ÷¡£

    µÏÍþÖƵÏÍþ¹ú¼Ê²»³Ðŵ»ò±£Ö¤Ç°Õ°ÐÔÐÅÏ¢µÄ׼ȷÐÔ¡¢¼°Ê±ÐÔ»òÍêÕûÐÔ£¬²¢ÇÒ²»³Ðµ£¸üлòÐÞ¶©ÕâЩǰհÐÔÉùÃ÷µÄÒåÎñ¡£ÎÞÂÛÊǵÏÍþÖƵÏÍþ¹ú¼Ê»¹ÊÇÆäÈκζ­Ê¡¢Ô±¹¤»ò´úÀíÈË£¬¾ù²»¶ÔÈκÎÖ¤Ã÷²»×¼È·»òÎÞ·¨ÊµÏÖµÄÇ°Õ°ÐÔÉùÃ÷¸ºÔð£¬Ò²²»¶ÔÒòÒÀÀµ±¾ÐÂΟåÖÐÌṩµÄÐÅÏ¢¶ø²úÉúµÄÈκÎËðʧ»òË𺦸ºÔ𣬰üÀ¨µ«²»ÏÞÓÚÖ±½Ó¡¢Å¼È»¡¢¼ä½Ó»ò³Í·£ÐÔµÄË𺦡£





    ¡¾ÍøÕ¾µØͼ¡¿¡¾sitemap¡¿